Merck

What Does Merck, Schering-Plough Deal Mean?

Armen Hareyan — Mon, 09 Mar 2009 09:14:28 -0500

As Marck buys Schering-Plough expect some noise from the drug company share holders.

The deal between Marck and Schering-Plough is a $41.1 billion cash and stock deal.

Merck today released the following statement that we present in brief.

JAMA duped by ghostwritten paper about VIOXX

Armen Hareyan — Wed, 16 Apr 2008 15:50:19 -0500

JAMA's editor, Catherine D. DeAngelis, said her journal had been duped by a ghostwritten manuscript in 2002 that compared Vioxx with two competitors' drugs for knee pain, and she acknowledged that editors bore some responsibility, writes Philly Inquirer's Kari Stark.

Vioxx Studies: Ghostwriters And Merck Sponsorship

Armen Hareyan — Tue, 15 Apr 2008 16:31:15 -0500

While you thought that those Vioxx studies in medical journals were independent, hands-off affairs that may not have been necessarily true. An examination of medical journal articles about Vioxx and court documents from Vioxx lawsuits found that Merck employees or ghostwriters were frequently involved in various articles, but the primary authors were often academics who actually had little to do with the studies or didn’t always disclose financial ties to Merck.

Schering-Plough, Merck In Panic As Another Vytorin Trial Delayed

Armen Hareyan — Mon, 31 Mar 2008 07:05:51 -0500

Things are getting more and more scary over at Schering-Plough and Merck as the problems with the cholesterol lowering drugs are looming and Lehman downgraded the stock of Merck. Most readers are aware of the ongoing Vytorin scandal and the Enhance trial debacle.

Singulair Side Effects Possibly Include Suicide

Armen Hareyan — Fri, 28 Mar 2008 15:30:32 -0500

FDA has started to look into the additional side effects of Merck's Singulair drug for Asthma treatment as reports link suicidal thoughts to Singulair.

Merck KGaA, rise in profits

seher — Mon, 18 Feb 2008 09:46:02 -0600

Merck KGaA, the world's biggest maker of liquid crystals for televisions, stated fourth- quarter profit .

Hib Vaccine Recall By Merck Due To Contamination

Armen Hareyan — Wed, 12 Dec 2007 22:47:24 -0600

Merck says it voluntarily recalls Hib vaccine due to contamination in the equipment in which the vaccine is made. Merck Hib vaccine recall includes around 1.2 million doses.

Vioxx Settlement To Cost Merck $4.85 Billion

Armen Hareyan — Fri, 09 Nov 2007 09:06:55 -0600

Merck Agreement Provides for $4.85 Billion Vioxx Settlement Payment.

Merck Reports Double-Digit Earnings-Per-Share Growth

Anastvatz — Mon, 23 Jul 2007 08:29:49 -0500

Merck & Co., Inc. announced on July 24 second-quarter 2007 results that reflected an increase in earnings per share of 12% fueled by strong performance across a broad range of the Company's products.

ARIAD and Merck Join Forces Against Cancer

Anastvatz — Thu, 12 Jul 2007 07:18:12 -0500

ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer

Merck's New Drug Approved by US FDA

Anastvatz — Mon, 14 May 2007 06:19:39 -0500

Merck & Co., Inc. confirmed on May 11th that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for the Company's New Drug Application (NDA) for EMENDÃ‚Â® (fosaprepitant dimeglumine) For Injection, also known as MK-0517, an investigational intravenous therapy for chemotherapy-induced nausea and vomiting (CINV).